Researchers at The Scripps Research Institute have discovered a potential new way to stimulate the immune system to prevent or clear a viral infection. By blocking the action of a key protein in the mouse immune system, they were able to boost immune “memory” in those mice - work that may one day help doctors increase the effectiveness of human vaccines designed to prevent viral infections…
Lees meer..

The United States can lead the world in deploying advanced biotechnology for biofuels and create thousands of new jobs by implementing policies to support the emerging industry…
Lees meer..

The Biotechnology Industry Organization (BIO) announced today its newest conference, the Livestock Biotech Summit, scheduled for September 28-30, 2010, in Sioux Falls, S.D…
Lees meer..

Tibotec Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies. Both ARTEMIS and TITAN evaluated the efficacy and safety of PREZISTA with ritonavir (r) vs…
Lees meer..

ChemoCentryx, Inc., announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases…
Lees meer..

Omeros Corporation (Nasdaq: OMER) announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company’s Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers…
Lees meer..

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced that Econiche(TM), the world’s first vaccine developed to reduce the shedding by cattle of Escherichia coli (E. coli) O157, has been cited in the February, 2010 issue of Scientific American (Vol. 302, # 2). The article, “The Art of Bacterial Warfare”, was written by Dr…
Lees meer..

Conatus Pharmaceuticals Inc. announced the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy…
Lees meer..

The International Serious Adverse Events Consortium (SAEC) has announced that it will collaborate with Duke University’s Center for Human Genome Variation to research the genetics of Clozapine-induced agranulocytosis (CIA), with the goal of identifying potential rare genetic variants predictive of this serious drug induced adverse event…
Lees meer..

Pfizer Inc. provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development…
Lees meer..